SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Memecoin on Cronos launched by the Cro Crow community

crow with knife

Crow with Knife ($CAW) is trending as its dedicated community highlights its fully decentralized nature, multichain expansion across major ecosystems like Solana and Base, and a deflationary burn mechanism. The token's active 'cult' of holders is buzzing about ongoing development, significant partnerships, and its perceived utility, making it a prominent discussion point among meme coin enthusiasts.

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Innodata Inc. is trending as it approaches its Q4 earnings report, with community discussion centered on its strategic shift into Physical AI and Humanoid Robotics, coupled with aggressive recruitment and potential defense contracts. Investors are closely monitoring for growth acceleration, robust financial performance, and any emerging M&A speculation.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is trending as escalating global geopolitical tensions amplify the urgent demand for secure Western heavy rare earth supplies essential for defense and technology. The community is actively debating the strategic significance and potential undervaluation of CRML's Tanbreez project, while awaiting its Bankable Feasibility Study update and noting dynamic short interest.

Vertiv Holdings Co. engages in the design, manufacture, and service of critical digital infrastructure technology for data centers, communication networks, and commercial and industrial environments. It also offers power management products, switchgear and busbar products, thermal management products, integrated rack systems, modular solutions, and management systems for monitoring and controlling digital infrastructure. It operates through the following geographical segments: Americas, Asia Pacific, and Europe, Middle East, and Africa (EMEA). The Americas segment offers products and services sold for applications within the data center, communication networks, and commercial and industrial markets in North America and Latin America. The Asia Pacific segment includes products and services sold for applications within the data center, communication networks, and commercial or industrial markets throughout Greater China, Australia and New Zealand, Southeast Asia, and India. The EMEA segment focuses on products and services sold for applications within the data center, communication networks, and commercial and industrial markets in Europe, Middle East, and Africa. The company was founded in 1946 and is headquartered in Columbus, OH.

Vertiv Holdings Co - Ordinary Shares - Class A

Vertiv Holdings Co

Vertiv Holdings is trending due to its upcoming inclusion in the S&P 500 index, expected to drive significant passive fund buying. This elevation underscores its strong position as a key provider of cooling and power infrastructure for the rapidly expanding AI and data center markets, sparking community discussions about sustained growth despite some near-term profit-taking.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is trending sharply on reports of an unexpected partnership with Novo Nordisk to sell GLP-1 weight-loss drugs, potentially ending a contentious lawsuit. The community is actively discussing the high short interest, anticipating a significant short squeeze fueled by this major catalyst.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as the community celebrates the imminent departure of a prominent FDA official, widely seen as a significant barrier to the approval of its Duchenne Muscular Dystrophy therapy, Deramiocel. This development, coupled with high anticipation for a late-breaking Phase 3 data presentation at a major medical conference next week, is fueling intense bullish sentiment and expectations for a rapid regulatory decision.

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

uniQure N.V.

uniQure NV

uniQure (QURE) is trending due to news that a prominent FDA official, previously seen as a hurdle for gene therapies like AMT-130, is stepping down, which has ignited speculation among investors about a potentially more favorable regulatory path. This has led to a significant surge in the stock, as the community debates whether this change, following prior FDA rejection of uniQure's clinical data, will genuinely derisk its Huntington's disease treatment or if the enthusiasm is overblown.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is buzzing as the CEO's recent discussion of 'curative outcomes' for its AML therapies drives community speculation of groundbreaking REGAL trial data and a potential buyout, intensified by an ongoing AML conference and growing short squeeze chatter.

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Marvell Technology is trending following a strong earnings beat and optimistic guidance driven by accelerating AI data center demand, with the community actively buying dips on long-term growth prospects. However, some traders are wary of a potential fade after unfulfilled S&P 500 inclusion expectations and historical volatility.

GSI Technology, Inc. engages in the design, development and marketing of memory products primarily for the networking, and telecommunications markets. Its product includes Static Random Access Memory, or SRAM, which incorporated in networking and telecommunications equipment, such as routers, switches, wide area network infrastructure equipment, wireless base stations and network access equipment. It also offers services to the ongoing needs of the military, industrial, test and measurement equipment, automotive and medical markets for SRAMs .The company was founded by Lee-Lean Shu and Robert Yau in March 1995 and is headquartered in Sunnyvale, CA.

GSI Technology Inc

GSI Technology is trending amid its government-backed AI security project and an upcoming conference presentation, though community sentiment remains highly polarized between bullish excitement over its efficient edge AI chips and strong allegations of management deception and product limitations.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR (E7777) Dosing Prior to Commercial CART Therapy in HighRisk Diffuse Large BCell Lymphoma

Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR (E7777) Dosing Prior to Commercial CART Therapy in HighRisk Diffuse Large BCell Lymphoma Citius Oncology Announces...

Citius Oncology, Inc. (NASDAQ:CTOR) Short Interest Update

Citius Oncology, Inc. (NASDAQ:CTOR - Get Free Report) was the recipient of a significant decrease in short interest in the month of February. As of February 13th, there was short interest totaling...

Citius Oncology (NASDAQ:CTOR) Posts Earnings Results, Hits Estimates

Citius Oncology (NASDAQ:CTOR - Get Free Report) released its quarterly earnings results on Friday. The company reported ($0.06) earnings per share for the quarter, hitting the consensus estimate of...

Citius Oncology Q1 Earnings Summary & Key Takeaways

Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR

Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of...

Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR

Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR PR Newswire...

Citius Oncology Expands International Distribution of LYMPHIR to European Union Through Exclusive Agreement with Uniphar

Citius Oncology Expands International Distribution of LYMPHIR to European Union Through Exclusive Agreement with Uniphar Citius Oncology Expands International Distribution of LYMPHIR to European...

Citius Oncology, Inc. (NASDAQ:CTOR) Short Interest Up 22.3% in January

Citius Oncology, Inc. (NASDAQ:CTOR - Get Free Report) was the recipient of a significant growth in short interest during the month of January. As of January 15th, there was short interest totaling...

Short Interest in Citius Oncology, Inc. (NASDAQ:CTOR) Expands By 51.2%

Citius Oncology, Inc. (NASDAQ:CTOR - Get Free Report) was the target of a significant growth in short interest in December. As of December 31st, there was short interest totaling 983,877 shares, a...

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Citius Oncology, Inc. (NASDQ: CTOR)

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Citius Oncology, Inc. (NASDQ: CTOR) SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of...

Citius Oncology, Inc. is a biopharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.

Current Price	$1.02
Prev Close	$1.07
Open	$1.06
Dividend Yield	0.00%
50-Day Moving Average	$1.12
Beta	-2.47
Avg. Volume	148,956.72
PE Ratio	-3.47

52-Week High	$6.19
52-Week Low	$0.5506
Market Capitalization	$94.45M
EPS (Annual)	-$0.338
Price to Book	1.55
Revenue Per Employee	N/A

CTOR
Citius Oncology Inc.

Feed

News

Sentiment

Fundamentals

Info

Latest CTOR News

CTORCitius Oncology Inc.